Oncology drug dosages and regimens are sometimes inadequately characterized prior to registration trials. The “more is better” paradigm is still used for dose selection, despite the recognition that targeted therapies require alternative approaches for dose optimization.
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.